Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Belgium | Chile | Dominican Republic | Egypt | France | Greece | Hungary | India | Ireland | Italy | Luxembourg | Morocco | Pakistan | Peru | Portugal | Spain | Taiwan | Tunisia
Approved Indications: None
Known Adverse Events: None
Company: University Hospital Of Clermont-Ferrand
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Osteoarthritis, Knee|Osteoarthritis, Hip
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
RBHP 2022 DUALE | P4 |
Not yet recruiting |
Osteoarthritis, Knee|Osteoarthritis, Hip |
2025-03-01 |